Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

被引：19
|
作者：
Pratz, Keith W. [1 ]
Cherry, Mohamad [2 ]
Altman, Jessica K. [3 ]
Cooper, Brenda [4 ]
Cruz, Jose Carlos [5 ]
Jurcic, Joseph G. [6 ]
Levis, Mark J. [7 ]
Lin, Tara L.
Perl, Alexander E. [8 ]
Podoltsev, Nikolai A. [9 ]
Schiller, Gary J. [10 ]
Liu, Chaofeng [11 ]
Bahceci, Erkut [11 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Univ Hosp Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Cleveland, OH USA
[5] Methodist Phys Practices, San Antonio, TX USA
[6] Columbia Univ, Med Ctr, New York, NY USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Univ Penn, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA
[9] Yale Sch Med, New Haven, CT USA
[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[11] Astellas Pharma Global Dev, Northbrook, IL USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110975
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
564
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Pratz, Keith
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark J.
    Lin, Tara L.
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Liu, Chaofeng
    Bahceci, Erkut
    BLOOD, 2017, 130
  • [2] A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results
    Pratz, Keith W.
    Cherry, Mohamad
    Podoltsev, Nikolai A.
    Altman, Jessica K.
    Perl, Alexander E.
    Cooper, Brenda W.
    Jurcic, Joseph G.
    Lin, Tara L.
    Schiller, Gary J.
    Wu, Ruishan
    Hill, Jason E.
    Gill, Stanley C.
    James, Angela
    Rich, Elizabeth Shima
    Hasabou, Nahla
    Levis, Mark J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S230 - S230
  • [3] A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
    Pratz, Keith W.
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark
    Lin, Tara
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Hill, Jason E.
    James, Angela
    Lu, Qiaoyang
    Tiu, Ramon V.
    BLOOD, 2020, 136
  • [4] Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
    Altman, Jessica K.
    Foran, James M.
    Pratz, Keith W.
    Trone, Denise
    Cortes, Jorge E.
    Tallman, Martin S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 213 - 221
  • [5] Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
    Pratz, Keith W.
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Podoltsev, Nikolai A.
    Cruz, Jose Carlos
    Lin, Tara L.
    Schiller, Gary J.
    Jurcic, Joseph G.
    Asch, Adam
    Wu, Ruishan
    Hill, Jason E.
    Gill, Stanley C.
    James, Angela J.
    Rich, Elizabeth Shima
    Hasabou, Nahla
    Perl, Alexander E.
    Levis, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4236 - +
  • [6] A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia
    Sawa, Masashi
    Miyamoto, Toshihiro
    Kim, Hee-Je
    Hiramatsu, Yasushi
    Cheong, June-Won
    Ikezoe, Takayuki
    Naoe, Tomoki
    Akashi, Koichi
    Morita, Satoshi
    Kosako, Masanori
    Ikegaya, Moyu
    Terada, Wataru
    Kadokura, Takeshi
    Hill, Jason
    Miyawaki, Shuichi
    Gill, Stanley C.
    Heinloth, Alexandra
    Hasabou, Nahla
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (01) : 56 - 67
  • [7] Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
    Altman, Jessica K.
    Foran, James M.
    Pratz, Keith W.
    Trone, Denise
    Gammon, Guy
    Cortes, Jorge E.
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [8] Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy
    Zarzour, Ahmad
    Nazha, Aziz
    Kalaycio, Matt
    Patel, Bhumika J.
    Gerds, Aaron T.
    Clemente, Michael J.
    Hirsch, Cassandra M.
    Carew, Jennifer S.
    Advani, Anjali S.
    Sanikommu, Srinivasa R.
    Przychodzen, Bartlomiej
    Carraway, Hetty E.
    Mukherjee, Sudipto
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [9] Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
    Qi, Junyuan
    Choi, Ilseung
    Ota, Shuichi
    Ichikawa, Satoshi
    Fujishima, Naohito
    Iida, Hiroatsu
    Sugiura, Isamu
    Sugiura, Koichi
    Murata, Yasuharu
    Inoue, Hiroyuki
    Ohwada, Shoichi
    Wang, Jianxiang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (05): : 560 - 571
  • [10] Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
    Montiel-Esparza, Raul
    Knaus, Hanna A.
    Zeidner, Joshua F.
    Vulic, Ante
    Prince, Gabrielle T.
    Smith, B. Douglas
    Levis, Mark J.
    Streicher, Howard
    Karp, Judith E.
    Luznik, Leo
    Gojo, Ivana
    BLOOD, 2015, 126 (23)
12345